VK2735 vs Zepbound: Same Mechanism, Different Stage

VK2735 and Zepbound are built on the same core mechanism (both activate GLP-1 and GIP), which makes this less a battle of biology and more a question of development stage and format. Zepbound is approved, proven, and available; VK2735 is investigational but offers something Zepbound doesn’t, an oral pill option alongside its injection. Here’s how Viking’s candidate compares to the established dual agonist.

The Same Two Targets

The mechanistic similarity is the headline. Zepbound (tirzepatide) is a dual agonist activating the GLP-1 and GIP receptors. VK2735 targets the same two receptors. So in principle, they work the same way, which is part of why VK2735 has drawn attention as a potential future competitor to tirzepatide. The differences lie in development stage, format, and how the specific molecules perform.

Head to Head

Weight Loss: Different Trial Lengths Make Comparison Tricky

Here’s an important caveat. Zepbound’s up-to-21% figure comes from a 72-week trial, while VK2735’s data so far comes from much shorter studies (around 13 weeks), where it produced double-digit weight loss with results still climbing. Tirzepatide’s evidence came from its SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022. Because VK2735’s trials are so much shorter, we can’t yet say how it would compare over a full year, so a direct efficacy verdict isn’t possible. Its early results are promising, but its long-term ceiling is unknown.

VK2735’s Potential Advantage: A Pill Option

What VK2735 offers that Zepbound doesn’t is format flexibility. Viking is developing it as both an injection and an oral tablet, using the same drug. If both succeed, patients could choose a pill or an injection, or potentially use the injection to lose weight and a pill to maintain it. Zepbound is injection-only. Consider a hypothetical patient who wants a tirzepatide-style dual agonist but strongly prefers pills: VK2735’s oral version could eventually fill that gap, though it’s not available yet.

Availability: Zepbound Wins Decisively

For now, this settles it. Zepbound is approved, proven over long trials, and available today. VK2735, despite its appealing oral option and similar mechanism, is investigational and only accessible through clinical trials, with phase 3 testing underway. A promising drug in development can’t be chosen over an approved one that’s ready now.

What This Means for You Right Now

VK2735 is not available, and TrimRx does not offer it. Zepbound (tirzepatide) is among the brand options TrimRx offers, alongside compounded tirzepatide and compounded semaglutide and other brand GLP-1 medications. If you want a proven dual-agonist option now, tirzepatide-based treatment delivers it, while VK2735 remains a future prospect to watch, especially for its oral potential.

Frequently Asked Questions

Is VK2735 as effective as Zepbound?

It’s too early to say. VK2735 uses the same GLP-1/GIP mechanism as Zepbound and showed promising double-digit weight loss, but only in short (roughly 13-week) trials, versus Zepbound’s up-to-21% over 72 weeks. Its long-term efficacy isn’t yet known.

What does VK2735 offer that Zepbound doesn’t?

An oral pill option. VK2735 is being developed as both an injection and a pill, while Zepbound is injection-only. That could give future patients more format flexibility, but VK2735 isn’t available yet.

Can I get VK2735?

No. VK2735 is investigational and available only through clinical trials. Zepbound is FDA approved and available, and TrimRx offers tirzepatide-based options.

To focus on what you can actually start with today, you can explore the options available to you now with a licensed provider.

This information is for educational purposes and is not medical advice. VK2735 is investigational and not FDA approved; details and timelines may change. Consult a healthcare provider before starting any medication. Individual results may vary.